Insider · CIK 0001277495
Carsten Boess
Files at RCKT (ROCKET PHARMACEUTICALS, INC.), RNA (Avidity Biosciences, Inc.), RNA (Atrium Therapeutics, Inc.). First filing -, latest -.
In brief
Carsten Boess files SEC Form 4 as director at RCKT (ROCKET PHARMACEUTICALS, INC.), and also at RNA (Avidity Biosciences, Inc.), RNA (Atrium Therapeutics, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Carsten Boess has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Feb 6, 2025 | Achilles Therapeutics plc | 25,000 | $34k | Feb 4, 2025 | none |
Transactions
Every row this insider has filed, 13 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 18, 2026 | RCKT ROCKET PHARMACEUTICALS, INC. | AGrant or award Common Stock | +22,862 | $0.00 | $0 | 52,862 | Jul 6, 2026 |
| Jun 18, 2026 | RCKT ROCKET PHARMACEUTICALS, INC. | AGrant or award Stock Option (Right to Buy)derivative | +64,860 | $0.00 | $0 | 64,860 | Jul 6, 2026 |
| Feb 27, 2026 | RNA Atrium Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +20,000 | $0.00 | $0 | 20,000 | Mar 2, 2026 |
| Feb 27, 2026 | RNA Avidity Biosciences, Inc. | DDisposition to issuer Common Stock | -6,692 | - | - | 0 | Feb 27, 2026 |
| Feb 27, 2026 | RNA Avidity Biosciences, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -10,034 | - | - | 0 | Feb 27, 2026 |
| Feb 27, 2026 | RNA Avidity Biosciences, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -13,489 | - | - | 0 | Feb 27, 2026 |
| Feb 27, 2026 | RNA Avidity Biosciences, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -22,000 | - | - | 0 | Feb 27, 2026 |
| Feb 27, 2026 | RNA Avidity Biosciences, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -22,000 | - | - | 0 | Feb 27, 2026 |
| Feb 27, 2026 | RNA Avidity Biosciences, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -15,000 | - | - | 0 | Feb 27, 2026 |
| Feb 27, 2026 | RNA Avidity Biosciences, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -20,858 | - | - | 0 | Feb 27, 2026 |
| Jun 18, 2025 | RCKT ROCKET PHARMACEUTICALS, INC. | AGrant or award Common Stock | +30,000 | $0.00 | $0 | 30,000 | Jul 18, 2025 |
| Jun 10, 2025 | RNA Avidity Biosciences, Inc. | AGrant or award Common Stock | +6,692 | $0.00 | $0 | 6,692 | Jun 12, 2025 |
| Jun 10, 2025 | RNA Avidity Biosciences, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +10,034 | $0.00 | $0 | 10,034 | Jun 12, 2025 |
Questions about Carsten Boess
Answered from the filings on this page, as of the latest one.
Is Carsten Boess buying or selling?
Carsten Boess has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Carsten Boess's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Carsten Boess has 0.
Where does Carsten Boess file Form 4?
Carsten Boess has filed Form 4 at RCKT (ROCKET PHARMACEUTICALS, INC.); RNA (Avidity Biosciences, Inc.); RNA (Atrium Therapeutics, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.